Depression and cardiovascular disease

Trends in Cardiovascular Medicine

Volumn 25, Issue 7, 2015, Pages 614-622

  Bradley, Steven M ^a,b,c   Rumsfeld, John S ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COGNITIVE THERAPY; COST OF ILLNESS; DEPRESSION; DROWSINESS; EVIDENCE BASED MEDICINE; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HEALTH BEHAVIOR; HEALTH STATUS; HIGH RISK PATIENT; HUMAN; INSOMNIA; MORTALITY; OUTCOMES RESEARCH; PHYSICAL INACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCREENING; SEXUAL DYSFUNCTION; SIDE EFFECT; TELEHEALTH; WEIGHT GAIN; ANIMAL; CARDIOVASCULAR DISEASES; COOPERATION; INTERDISCIPLINARY COMMUNICATION; PATIENT CARE; PREDICTIVE VALUE; PSYCHOLOGY; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; COOPERATIVE BEHAVIOR; DEPRESSION; HUMANS; INTERDISCIPLINARY COMMUNICATION; PATIENT CARE TEAM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84941996218     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2015.02.002     Document Type: Review

References (103)

1. Hirschfeld R.M., Keller M.B., Panico S., Arons B.S., Barlow D., Davidoff F., et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. J Am Med Assoc 1997, 277:333-340.
2. Whooley M.A. Depression and cardiovascular disease: healing the broken-hearted. J Am Med Assoc 2006, 295:2874-2881.
3. Anda R., Williamson D., Jones D., Macera C., Eaker E., Glassman A., et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology 1993, 4:285-294.
4. Pratt L.A., Ford D.E., Crum R.M., Armenian H.K., Gallo J.J., Eaton W.W. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996, 94:3123-3129.
5. Lett H.S., Blumenthal J.A., Babyak M.A., Sherwood A., Strauman T., Robins C., et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004, 66:305-315.
6. Brown J.M., Stewart J.C., Stump T.E., Callahan C.M. Risk of coronary heart disease events over 15 years among older adults with depressive symptoms. Am J Geriatr Psychiatry 2011, 19:721-729.
7. Ford D.E., Mead L.A., Chang P.P., Cooper-Patrick L., Wang N.Y., Klag M.J. Depression is a risk factor for coronary artery disease in men: the precursors study. Arch Intern Med 1998, 158:1422-1426.
8. Ariyo A.A., Haan M., Tangen C.M., Rutledge J.C., Cushman M., Dobs A., et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation 2000, 102:1773-1779.
9. Ferketich A.K., Schwartzbaum J.A., Frid D.J., Moeschberger M.L. Depression as an antecedent to heart disease among women and men in the NHANES I study. National Health and Nutrition Examination Survey. Arch Intern Med 2000, 160:1261-1268.
10. Penninx B.W., Beekman A.T., Honig A., Deeg D.J., Schoevers R.A., van Eijk J.T., et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001, 58:221-227.
11. Surtees P.G., Wainwright N.W.J., Luben R.N., Wareham N.J., Bingham S.A., Khaw K.T. Depression and ischemic heart disease mortality: evidence from the EPIC-Norfolk United Kingdom prospective cohort study. Am J Psychiatry 2008, 165:515-523.
12. Pan A., Sun Q., Okereke O.I., Rexrode K.M., Hu F.B. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. J Am Med Assoc 2011, 306:1241-1249.
13. Grenon S.M., Hiramoto J., Smolderen K.G., Vittinghoff E., Whooley M.A., Cohen B.E. Association between depression and peripheral artery disease: insights from the heart and soul study. J Am Heart Assoc 2012, 1:e002667.
14. Charlson F.J., Moran A.E., Freedman G., Norman R.E., Stapelberg N.J.C., Baxter A.J., et al. The contribution of major depression to the global burden of ischemic heart disease: a comparative risk assessment. BMC Med 2013, 11:250.
15. Frasure-Smith N., Lespérance F., Talajic M. Depression following myocardial infarction. Impact on 6-month survival. J Am Med Assoc 1993, 270:1819-1825.
16. Frasure-Smith N., Lespérance F., Juneau M., Talajic M., Bourassa M.G. Gender, depression, and one-year prognosis after myocardial infarction. Psychosom Med 1999, 61:26-37.
17. Lespérance F., Frasure-Smith N., Juneau M., Théroux P. Depression and 1-year prognosis in unstable angina. Arch Intern Med 2000, 160:1354-1360.
18. Lespérance F., Frasure-Smith N., Talajic M., Bourassa M.G. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation 2002, 105:1049-1053.
19. Van Melle J.P., de Jonge P., Spijkerman T.A., Tijssen J.G.P., Ormel J., van Veldhuisen D.J., et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 2004, 66:814-822.
20. Barth J., Schumacher M., Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 2004, 66:802-813.
21. Parashar S., Rumsfeld J.S., Spertus J.A., Reid K.J., Wenger N.K., Krumholz H.M., et al. Time course of depression and outcome of myocardial infarction. Arch Intern Med 2006, 166:2035-2043.
22. Lichtman J.H., Froelicher E.S., Blumenthal J.A., Carney R.M., Doering L.V., Frasure-Smith N., et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 2014, 129:1350-1369.
23. Jiang W., Alexander J., Christopher E., Kuchibhatla M., Gaulden L.H., Cuffe M.S., et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001, 161:1849-1856.
24. Van den Broek K.C., Defilippi C.R., Christenson R.H., Seliger S.L., Gottdiener J.S., Kop W.J. Predictive value of depressive symptoms and B-type natriuretic peptide for new-onset heart failure and mortality. Am J Cardiol 2011, 107:723-729.
25. Sherwood A., Blumenthal J.A., Hinderliter A.L., Koch G.G., Adams K.F., Dupree C.S., et al. Worsening depressive symptoms are associated with adverse clinical outcomes in patients with heart failure. J Am Coll Cardiol 2011, 57:418-423.
26. Ruo B., Rumsfeld J.S., Hlatky M.A., Liu H., Browner W.S., Whooley M.A. Depressive symptoms and health-related quality of life: the Heart and Soul Study. J Am Med Assoc 2003, 290:215-221.
27. Rumsfeld J.S., Magid D.J., Plomondon M.E., Sales A.E., Grunwald G.K., Every N.R., et al. History of depression, angina, and quality of life after acute coronary syndromes. Am Heart J 2003, 145:493-499.
28. De Jonge P., Spijkerman T.A., van den Brink R.H.S., Ormel J. Depression after myocardial infarction is a risk factor for declining health related quality of life and increased disability and cardiac complaints at 12 months. Heart 2006, 92:32-39.
29. Rumsfeld J.S., Havranek E., Masoudi F.A., Peterson E.D., Jones P., Tooley J.F., et al. Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. J Am Coll Cardiol 2003, 42:1811-1817.
30. Vaccarino V., Kasl S.V., Abramson J., Krumholz H.M. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol 2001, 38:199-205.
31. Frasure-Smith N., Lespérance F., Gravel G., Masson A., Juneau M., Talajic M., et al. Depression and health-care costs during the first year following myocardial infarction. J Psychosom Res 2000, 48:471-478.
32. Sullivan M., Simon G., Spertus J., Russo J. Depression-related costs in heart failure care. Arch Intern Med 2002, 162:1860-1866.
33. Veith R.C., Lewis N., Linares O.A., Barnes R.F., Raskind M.A., Villacres E.C., et al. Sympathetic nervous system activity in major depression. Basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry 1994, 51:411-422.
34. Otte C., Neylan T.C., Pipkin S.S., Browner W.S., Whooley M.A. Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry 2005, 162:2139-2145.
35. Barton D.A., Dawood T., Lambert E.A., Esler M.D., Haikerwal D., Brenchley C., et al. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk?. J Hypertens 2007, 25:2117-2124.
36. Hughes J.W., Watkins L., Blumenthal J.A., Kuhn C., Sherwood A. Depression and anxiety symptoms are related to increased 24-hour urinary norepinephrine excretion among healthy middle-aged women. J Psychosom Res 2004, 57:353-358.
37. Nemeroff C.B., Widerlöv E., Bissette G., Walléus H., Karlsson I., Eklund K., et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984, 226:1342-1344.
38. Otte C., Marmar C.R., Pipkin S.S., Moos R., Browner W.S., Whooley M.A. Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: the Heart and Soul Study. Biol Psychiatry 2004, 56:241-247.
39. Biegon A., Essar N., Israeli M., Elizur A., Bruch S., Bar-Nathan A.A. Serotonin 5-HT2 receptor binding on blood platelets as a state dependent marker in major affective disorder. Psychopharmacology 1990, 102:73-75.
40. Laghrissi-Thode F., Wagner W.R., Pollock B.G., Johnson P.C., Finkel M.S. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997, 42:290-295.
41. Nemeroff C.B., Musselman D.L. Are platelets the link between depression and ischemic heart disease?. Am Heart J 2000, 140:57-62.
42. Serebruany V.L., Glassman A.H., Malinin A.I., Sane D.C., Finkel M.S., Krishnan R.R., et al. Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. Blood Coagul Fibrinolysis 2003, 14:563-567.
43. Sherwood A., Hinderliter A.L., Watkins L.L., Waugh R.A., Blumenthal J.A. Impaired endothelial function in coronary heart disease patients with depressive symptomatology. J Am Coll Cardiol 2005, 46:656-659.
44. Cooper D.C., Tomfohr L.M., Milic M.S., Natarajan L., Bardwell W.A., Ziegler M.G., et al. Depressed mood and flow-mediated dilation: a systematic review and meta-analysis. Psychosom Med 2011, 73:360-369.
45. Chen H., Zhang L., Zhang M., Song X., Zhang H., Liu Y., et al. Relationship of depression, stress and endothelial function in stable angina patients. Physiol Behav 2013, 118:152-158.
46. Di Stefano R., Felice F., Pini S., Mazzotta G., Bovenzi F.M., Bertoli D., et al. Impact of depression on circulating endothelial progenitor cells in patients with acute coronary syndromes: a pilot study. J Cardiovasc Med 2014, 15:353-359.
47. Pizzi C., Manzoli L., Mancini S., Costa G.M. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. Eur Heart J 2008, 29:1110-1117.
48. Suarez E.C., Krishnan R.R., Lewis J.G. The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom Med 2003, 65:362-368.
49. Penninx B.W., Kritchevsky S.B., Yaffe K., Newman A.B., Simonsick E.M., Rubin S., et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol Psychiatry 2003, 54:566-572.
50. Anisman H., Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Ann Med 2003, 35:2-11.
51. McCaffery J.M., Frasure-Smith N., Dubé M.P., Théroux P., Rouleau G.A., Duan Q., et al. Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom Med 2006, 68:187-200.
52. Vaccarino V., Johnson B.D., Sheps D.S., Reis S.E., Kelsey S.F., Bittner V., et al. Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: the National Heart, Lung, and Blood Institute-sponsored WISE study. J Am Coll Cardiol 2007, 50:2044-2050.
53. Stewart J.C., Rand K.L., Muldoon M.F., Kamarck T.W. A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav Immun 2009, 23:936-944.
54. Carney R.M., Saunders R.D., Freedland K.E., Stein P., Rich M.W., Jaffe A.S. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol 1995, 76:562-564.
55. Krittayaphong R., Cascio W.E., Light K.C., Sheffield D., Golden R.N., Finkel J.B., et al. Heart rate variability in patients with coronary artery disease: differences in patients with higher and lower depression scores. Psychosom Med 1997, 59:231-235.
56. Carney R.M., Freedland K.E., Rich M.W., Smith L.J., Jaffe A.S. Ventricular tachycardia and psychiatric depression in patients with coronary artery disease. Am J Med 1993, 95:23-28.
57. Frasure-Smith N., Lespérance F., Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995, 91:999-1005.
58. Luukinen H., Laippala P., Huikuri H.V. Depressive symptoms and the risk of sudden cardiac death among the elderly. Eur Heart J 2003, 24:2021-2026.
59. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008, 31:464-468.
60. Stetler C., Miller G.E. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med 2011, 73:114-126.
61. Hariri A.R., Mattay V.S., Tessitore A., Kolachana B., Fera F., Goldman D., et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002, 297:400-403.
62. Ogilvie A.D., Battersby S., Bubb V.J., Fink G., Harmar A.J., Goodwim G.M., et al. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 1996, 347:731-733.
63. Romanelli J., Fauerbach J.A., Bush D.E., Ziegelstein R.C. The significance of depression in older patients after myocardial infarction. J Am Geriatr Soc 2002, 50:817-822.
64. DiMatteo M.R., Lepper H.S., Croghan T.W. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000, 160:2101-2107.
65. Gehi A., Haas D., Pipkin S., Whooley M.A. Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med 2005, 165:2508-2513.
66. Kronish I.M., Rieckmann N., Halm E.A., Shimbo D., Vorchheimer D., Haas D.C., et al. Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. J Gen Intern Med 2006, 21:1178-1183.
67. Rieckmann N., Kronish I.M., Haas D., Gerin W., Chaplin W.F., Burg M.M., et al. Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes. Am Heart J 2006, 152:922-927.
68. Rieckmann N., Gerin W., Kronish I.M., Burg M.M., Chaplin W.F., Kong G., et al. Course of depressive symptoms and medication adherence after acute coronary syndromes: an electronic medication monitoring study. J Am Coll Cardiol 2006, 48:2218-2222.
69. Ziegelstein R.C., Fauerbach J.A., Stevens S.S., Romanelli J., Richter D.P., Bush D.E. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med 2000, 160:1818-1823.
70. Bonnet F., Irving K., Terra J.L., Nony P., Berthezène F., Moulin P. Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease. Atherosclerosis 2005, 178:339-344.
71. Doyle F., Rohde D., Rutkowska A., Morgan K., Cousins G., McGee H. Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with coronary heart disease: 1990 to 2013. Psychosom Med 2014, 76:44-57.
72. McKellar J.D., Humphreys K., Piette J.D. Depression increases diabetes symptoms by complicating patients' self-care adherence. Diabetes Educ 2004, 30:485-492.
73. Win S., Parakh K., Eze-Nliam C.M., Gottdiener J.S., Kop W.J., Ziegelstein R.C. Depressive symptoms, physical inactivity and risk of cardiovascular mortality in older adults: the Cardiovascular Health Study. Heart 2011, 97:500-505.
74. Whooley M.A., de Jonge P., Vittinghoff E., Otte C., Moos R., Carney R.M., et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. J Am Med Assoc 2008, 300:2379-2388.
75. Serebruany V.L., Glassman A.H., Malinin A.I., Nemeroff C.B., Musselman D.L., van Zyl L.T., et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003, 108:939-944.
76. Serebruany V.L., O'Connor C.M., Gurbel P.A. Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. Am J Cardiol 2001, 87:1398-1400.
77. Serebruany V.L., Glassman A.H., Malinin A.I., Atar D., Sane D.C., Oshrine B.R., et al. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail 2003, 5:517-521.
78. Tuglu C., Kara S.H., Caliyurt O., Vardar E., Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 2003, 170:429-433.
79. McFarlane A., Kamath M.V., Fallen E.L., Malcolm V., Cherian F., Norman G. Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J 2001, 142:617-623.
80. Balogh S., Fitzpatrick D.F., Hendricks S.E., Paige S.R. Increases in heart rate variability with successful treatment in patients with major depressive disorder. Psychopharmacol Bull 1993, 29:201-206.
81. Barton D.A., Esler M.D., Dawood T., Lambert E.A., Haikerwal D., Brenchley C., et al. Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy. Arch Gen Psychiatry 2008, 65:38-46.
82. Glassman A.H., O'Connor C.M., Califf R.M., Swedberg K., Schwartz P., Bigger J.T., et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. J Am Med Assoc 2002, 288:701-709.
83. Swenson J.R., O'Connor C.M., Barton D., Van Zyl L.T., Swedberg K., Forman L.M., et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am J Cardiol 2003, 92:1271-1276.
84. van Melle J.P., de Jonge P., Honig A., Schene A.H., Kuyper A.M.G., Crijns H.J., et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry 2007, 190:460-466.
85. Stewart J.C., Perkins A.J., Callahan C.M. Effect of collaborative care for depression on risk of cardiovascular events: data from the IMPACT randomized controlled trial. Psychosom Med 2014, 76:29-37.
86. Taylor C.B., Youngblood M.E., Catellier D., Veith R.C., Carney R.M., Burg M.M., et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005, 62:792-798.
87. Sauer W.H., Berlin J.A., Kimmel S.E. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003, 108:32-36.
88. Tiihonen J., Lonngvist J., Wahlbeck K., Klaukka T., Tanskanen A., Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006, 63:1358-1367.
89. Ko D.T., Hebert P.R., Coffey C.S., Sedrakyan A., Curtis J.P., Krumholz H.M. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. J Am Med Assoc 2002, 288:351-357.
90. Berkman L.F., Blumenthal J., Burg M., Carney R.M., Catellier D., Cowan M.J., et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. J Am Med Assoc 2003, 289:3106-3116.
91. Davidson K.W., Rieckmann N., Clemow L., Schwartz J.E., Shimbo D., Medina V., et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. Arch Intern Med 2010, 170:600-608.
92. Huffman J.C., Mastromauro C.A., Beach S.R., Celano C.M., DuBois C.M., Healy B.C., et al. Collaborative care for depression and anxiety disorders in patients with recent cardiac events: the Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized clinical trial. JAMA Intern Med 2014, 174:927-935.
93. O'Neil A., Taylor B., Sanderson K., Cyril S., Chan B., Hawkes A.L., et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the "MoodCare" randomized controlled trial. Ann Behav Med 2014, 48:163-174.
94. Rollman B.L., Belnap B.H., LeMenager M.S., Mazumdar S., Houck P.R., Counihan P.J., et al. Telephone-delivered collaborative care for treating post-CABG depression: a randomized controlled trial. J Am Med Assoc 2009, 302:2095-2103.
95. Huffman J.C., Mastromauro C.A., Sowden G., Fricchione G.L., Healy B.C., Januzzi J.L. Impact of a depression care management program for hospitalized cardiac patients. Circ Cardiovasc Qual Outcomes 2011, 4:198-205.
96. Katon W.J., Lin E.H.B., Von Korff M., Ciechanowski P., Ludman E.J., Young B., et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med 2010, 363:2611-2620.
97. Amin A.A., Jones A.M.H., Nugent K., Rumsfeld J.S., Spertus J.A. The prevalence of unrecognized depression in patients with acute coronary syndrome. Am Heart J 2006, 152:928-934.
98. Thombs B.D. No evidence for depression screening in cardiovascular care settings: a comment on CANMAT task force recommendations. Ann Clin Psychiatry 2012, 24:319-320.
99. Lichtman J.H., Bigger J.T., Blumenthal J.A., Frasure-Smith N., Kaufmann P.G., Lespérance F., et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 2008, 118:1768-1775.
100. McManus D., Pipkin S.S., Whooley M.A. Screening for depression in patients with coronary heart disease (data from the Heart and Soul Study). Am J Cardiol 2005, 96:1076-1081.
101. Kroenke K., Spitzer R.L., Williams J.B. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001, 16:606-613.
102. Hasnain M., Howland R.H., Vieweg W.V.R. Escitalopram and QTc prolongation. J Psychiatry Neurosci 2013, 38:E11.
103. Medicines and Healthcare products Regulatory Agency (MHRA). Citalopram and escitalopram: QT interval prolongation-new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings; 2001.